LARIMAR THERAPEUTICS INC
LRMRNASDAQTrading Snapshot
- Day Range
- $2.56 – $2.73
- 52-Week Range
- $1.92 – $6.42
- Volume (shares)
- 644,381.942
- Avg Volume (shares)
- —
- Shares Outstanding
- 103.9M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -1.3
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.66
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +33.5%
LARIMAR THERAPEUTICS INC
LRMR
StockOtter · stockotter.spaceAbout LARIMAR THERAPEUTICS INC
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
Small-cap stocks tend to fly under the radar. Often in startup stages, these companies can lack analyst coverage, be overlooked by institutional investors, and be illiquid due to low average trading volume.
Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Larimar (LRMR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings e
Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
BALA CYNWYD, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
BlackRock Inc. Buys New Position in Larimar Therapeutics, Inc. $LRMR
BlackRock Inc. purchased a new stake in Larimar Therapeutics, Inc. (NASDAQ: LRMR) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of “Buy” from Brokerages
Shares of Larimar Therapeutics, Inc. (NASDAQ: LRMR - Get Free Report) have earned a consensus recommendation of "Buy" from the ten research firms that are currently covering the company, MarketBeat.com reports. One inves